Women seeking testosterone treatment for menopausal symptoms are circumventing NHS barriers by misrepresenting themselves as men when purchasing from online pharmacies, according to health professionals in Wales. Dr Michelle Olver, a menopause specialist, reported observing patients with testosterone levels up to 12 times the safe amount due to unmonitored online purchases, which can result in permanent adverse effects including voice deepening, baldness, and clitoral enlargement. She advocates for a standardized Wales-wide approach to testosterone prescribing while emphasizing the importance of proper counseling and medical monitoring to maintain appropriate hormone levels.
Testosterone is a naturally occurring hormone that decreases with age, and evidence supports its use in treating reduced libido in post-menopausal women. While some women report additional benefits for energy and cognitive function, a study is currently underway in Wales to evaluate these anecdotal claims scientifically. The absence of a licensed testosterone medication for women in the UK means that male formulations are prescribed at significantly reduced doses. Healthcare guidelines recommend baseline blood testing and regular monitoring to ensure patients remain within the female physiological range for the hormone.
Access to testosterone through the NHS varies significantly across Wales’s seven health boards, creating what Dr Rebeccah Tomlinson characterizes as a “postcode lottery.” Some health boards restrict prescribing to specialists only, while others permit general practitioners to prescribe with varying levels of hospital specialist involvement. This inconsistency has led some women to seek private consultations and prescriptions, and in some cases, to resort to fraudulent online purchases when costs become prohibitive. Emma Thomas, co-founder of menopause support group Menopals Cardiff and Vale, noted that members frequently report being denied access by their GPs or surgeries.
Dr Olver indicated that her health board has established a dedicated testosterone clinic to manage growing demand, reflecting a substantial increase in referrals from primary care. The primary impediment to uniform prescribing standards is the lack of an approved testosterone product specifically formulated for women within the NHS, though such products have been available in other countries for many years and are accessible through private clinics across the UK. Healthcare professionals and women who have used testosterone agree the treatment is not universally appropriate and recommend individualized assessment and access to diverse hormone replacement options.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI